Methods of producing stem cell conditioned media
AssigneeNeuroFx, Inc.
InventorsKeith Leonard March, Brian H. Johnstone, Yansheng Du
Life of this patent
Estimating the term…
Abstract
Methods of producing stem cell conditioned media to treat mammalian injuries or insults. In at least one embodiment of a method of producing a stem cell conditioned media of the present disclosure, the method comprises the steps of culturing at least one stem cell in a first cell culture medium, replacing some or all of the first cell culture medium with a second cell culture medium and further culturing the at least one stem cell in the second cell culture medium, and collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains a cell culture byproduct effective to treat a mammalian insult or injury.
Claims20
A method of producing a stem cell conditioned media, the method comprising the steps of:
- culturing at least one mesenchymal stem cell in a first cell culture medium, the at least one mesenchymal stem cell derived from a mammal selected from the group consisting of a human, a mouse, and a rat;
- replacing some or all of the first cell culture medium with a second cell culture medium and further culturing the at least one mesenchymal stem cell in the second cell culture medium to generate a plurality of cultured cells;
- and
- collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains secretions from the plurality of cultured cells;
- wherein the step of culturing comprises culturing the at least one mesenchymal stem cell having a surface marker profile selected from the group consisting of lin−/CD45−/c-kit−/CD90+, lin−/CD45−/c-kit−/CD90+/Sca-1+, and lin−/CD45−/c-kit−/CD90+/CD34.
A method of producing a stem cell conditioned media, the method comprising the steps of:
- culturing at least one mesenchymal stem cell in a first cell culture medium having a first amount of growth factor, the at least one mesenchymal stem cell derived from a mammal selected from the group consisting of a human, a mouse, and a rat, and having a surface marker profile selected from the group consisting of lin−/CD45−/c-kit−/CD90+, lin−/CD45−/c-kit−/CD90+/Sca-1+, and lin−/CD45−/c-kit−/CD90+/CD34;
- replacing some or all of the first cell culture medium with a second cell culture medium having a second amount of growth factor and further culturing the at least one mesenchymal stem cell in the second cell culture medium to generate a plurality of cultured cells, the second amount of growth factor being less than the first amount;
- and
- collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains secretions from the plurality of cultured cells effective to treat a mammalian neural insult or injury.
A method of producing a stem cell conditioned media, the method comprising the steps of:
- culturing at least one mesenchymal stem cell in a first cell culture medium, the at least one mesenchymal stem cell derived from a mammal selected from the group consisting of a human, a mouse, and a rat;
- replacing some or all of the first cell culture medium with a second cell culture medium comprising a basal medium that is at least substantially growth factor-free and further culturing the at least one mesenchymal stem cell in the second cell culture medium to generate a plurality of cultured cells;
- and
- collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains secretions from the plurality of cultured cells and the second cell culture medium contains at least one factor selected from the group consisting of at least one angiogenic factor and at least one antiapoptotic factor;
- wherein the step of culturing comprises culturing the at least one mesenchymal stem cell having a surface marker profile selected from the group consisting of lin−/CD45−/c-kit−/CD90+, lin−/CD45−/c-kit−/CD90+/Sca-1+, and lin−/CD45−/c-kit−/CD90+/CD34.
Dependencies are inferred from the claim text.